What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?

Video interview with Francesc Bosch, MD who discusses a study involving glofitamab combined with polatuzumab vedotin for treatment of relapsed diffuse large b-cell lymphoma.